LS Investment Advisors LLC raised its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 1.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 76,703 shares of the biopharmaceutical company’s stock after buying an additional 843 shares during the quarter. LS Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $3,660,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Capital Financial Planning LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter valued at $28,000. Financial Gravity Wealth Inc. purchased a new stake in Bristol-Myers Squibb in the 1st quarter valued at $26,000. Well Done LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter valued at $30,000. Riverview Trust Co purchased a new stake in Bristol-Myers Squibb in the 4th quarter valued at $33,000. Finally, Trust Department MB Financial Bank N A purchased a new stake in Bristol-Myers Squibb in the 1st quarter valued at $32,000. Institutional investors own 74.09% of the company’s stock.
Shares of Bristol-Myers Squibb stock opened at $46.85 on Friday. Bristol-Myers Squibb Co has a 52 week low of $44.30 and a 52 week high of $63.69. The firm has a market capitalization of $76.63 billion, a PE ratio of 11.77, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77. The company has a current ratio of 1.93, a quick ratio of 1.79 and a debt-to-equity ratio of 0.37.
The company also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were paid a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a yield of 3.50%. The ex-dividend date of this dividend was Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is 41.21%.
Several equities analysts have recently commented on the company. ValuEngine raised Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 4th. Zacks Investment Research lowered Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Thursday, March 28th. Credit Suisse Group reaffirmed a “hold” rating and issued a $59.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, February 15th. BMO Capital Markets upped their price target on Bristol-Myers Squibb from $62.00 to $63.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. Finally, Bank of America decreased their price target on Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 19th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and eight have issued a buy rating to the company. Bristol-Myers Squibb has an average rating of “Hold” and an average price target of $57.64.
COPYRIGHT VIOLATION NOTICE: This report was first posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.baseballdailydigest.com/news/2019/05/19/ls-investment-advisors-llc-raises-position-in-bristol-myers-squibb-co-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Read More: What causes a recession?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.